Get exclusive money-saving offers and guides
Straight to your inbox
By signing up, you agree to the Finder
Privacy & Cookies Policy
and
Terms of Use, Disclaimer & Privacy Policy.
How to buy Pharmaxis shares
Own Pharmaxis shares in just a few minutes.
Investments
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Pharmaxis Ltd is a drug manufacturers-general business based in Australia. Pharmaxis shares (PXS) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Pharmaxis has a trailing 12-month revenue of around $27.2 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Pharmaxis
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Pharmaxis . Find the share by name or ticker symbol: PXS. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pharmaxis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Pharmaxis . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks
Finder Award
Our top pick for
Cheap broker fees
Finder Award
Our top pick for
Long-term investing
Finder Award
Pharmaxis share price
Use our graph to track the performance of PXS stocks over time.Pharmaxis shares at a glance
Information last updated 2021-06-18.
| 52-week range | $0.065 - $0.14 |
|---|---|
| 50-day moving average | $0.0813 |
| 200-day moving average | $0.0856 |
| Target price | $0.52 |
| PE ratio | 5.9231 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.013 |
Compare share trading platforms
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Pharmaxis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Pharmaxis price performance over time
Historical closes compared with the last close of A$0.08
| 1 week (2021-06-11) | 0.08 |
|---|---|
| 1 month (2021-05-19) | -3.61% |
| 3 months (2021-03-19) | -5.88% |
| 6 months (2020-12-18) | -9.09% |
| 1 year (2020-06-19) | 14.29% |
|---|---|
| 2 years (2019-06-19) | -66.67% |
| 3 years (2018-06-19) | -74.19% |
| 5 years (2016-06-17) | -68.00% |
Is Pharmaxis under- or over-valued?
Valuing Pharmaxis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pharmaxis 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pharmaxis 's P/E ratio
Pharmaxis 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Pharmaxis shares trade at around 6x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Pharmaxis 's EBITDA
Pharmaxis 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 million.
The EBITDA is a measure of a Pharmaxis 's overall financial performance and is widely used to measure a its profitability.
Pharmaxis financials
| Revenue TTM | $27.2 million |
|---|---|
| Gross profit TTM | $11.2 million |
| Return on assets TTM | -11.5% |
| Return on equity TTM | 163.01% |
| Profit margin | 18.43% |
| Book value | 0.003 |
| Market capitalisation | $34.8 million |
TTM: trailing 12 months
Pharmaxis share dividends
We're not expecting Pharmaxis to pay a dividend over the next 12 months.
Pharmaxis share price volatility
Over the last 12 months, Pharmaxis 's shares have ranged in value from as little as $0.065 up to $0.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Pharmaxis 's is 0.4693. This would suggest that Pharmaxis 's shares are less volatile than average (for this exchange).
Pharmaxis overview
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
-
Why the BHP, Rio and FMG share prices are rising
Shares in mining giants BHP, Rio Tinto and Fortescue Metals have climbed between 10%-16% in the last six months.
-
eBay EOFY sales: Best deals from Apple, KitchenAid and more
Score up to 65% off best-selling products with these top end of financial year offers.
-
Thinking about teeth aligners? Here’s how to make them more affordable
SPONSORED: Perfect teeth could be in closer reach than you think.
-
Your first look at the Billie Eilish x Air Jordan 1 sneaker collab
Featuring Billie's signature shade, here's what you need to know if you want to cop these kicks.
-
Amazon Prime Day 2021: Don’t miss these deals on 21 June
Amazon Prime Day is returning to Australia in the first half of 2021. Here are six online deals you need to know about.
-
How to buy TitanSwap (TITAN) in Australia
This guide will show you step-by-step instructions on how to buy the TitanSwap (TITAN) token as well as a list of exchanges you can trade it on.
-
Canterbury Bulldogs vs St George Illawarra Dragons NRL: Start time and watch free
The one-win Bulldogs return after a bye, hopefully refreshed and ready to meet the Dragons.
-
NSW first home owners tax reform offers 25K grants
First home buyers in NSW could be given up to $25,000 towards their first home purchase – find out if you're eligible.
-
24 PlayStation 5 consoles are up for grabs this long weekend
eBay is giving away 24 PlayStation 5 prize packs this long weekend - here's how to enter.
-
Does anyone actually need Twitter Blue?
Here's everything included in Twitter Blue and how much it costs.
Ask an Expert
